These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25167370)

  • 41. Azole-based non-peptidomimetic plasmepsin inhibitors.
    Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
    Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
    Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
    J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequence homology and structural analysis of plasmepsin 4 isolated from Indian Plasmodium vivax isolates.
    Rawat M; Vijay S; Gupta Y; Dixit R; Tiwari PK; Sharma A
    Infect Genet Evol; 2011 Jul; 11(5):924-33. PubMed ID: 21382523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'.
    Romeo S; Dell'Agli M; Parapini S; Rizzi L; Galli G; Mondani M; Sparatore A; Taramelli D; Bosisio E
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2931-4. PubMed ID: 15125962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
    Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
    J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
    Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
    J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Yield improvement and enzymatic dissection of Plasmodium falciparum plasmepsin V.
    Loymunkong C; Sittikul P; Songtawee N; Wongpanya R; Boonyalai N
    Mol Biochem Parasitol; 2019 Jul; 231():111188. PubMed ID: 31108131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibitors of Plasmepsin II-potential antimalarial agents.
    Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New inhibitors of the malaria aspartyl proteases plasmepsin I and II.
    Dahlgren A; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2003 Aug; 11(16):3423-37. PubMed ID: 12878137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.
    Carroll CD; Patel H; Johnson TO; Guo T; Orlowski M; He ZM; Cavallaro CL; Guo J; Oksman A; Gluzman IY; Connelly J; Chelsky D; Goldberg DE; Dolle RE
    Bioorg Med Chem Lett; 1998 Sep; 8(17):2315-20. PubMed ID: 9873534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609.
    Zhang R; Suwanarusk R; Malleret B; Cooke BM; Nosten F; Lau YL; Dao M; Lim CT; Renia L; Tan KS; Russell B
    J Infect Dis; 2016 Jan; 213(1):100-4. PubMed ID: 26136472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
    Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In Silico screening on the three-dimensional model of the Plasmodium vivax SUB1 protease leads to the validation of a novel anti-parasite compound.
    Bouillon A; Giganti D; Benedet C; Gorgette O; Pêtres S; Crublet E; Girard-Blanc C; Witkowski B; Ménard D; Nilges M; Mercereau-Puijalon O; Stoven V; Barale JC
    J Biol Chem; 2013 Jun; 288(25):18561-73. PubMed ID: 23653352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PEXEL is a proteolytic maturation site for both exported and non-exported
    Fierro MA; Muheljic A; Sha J; Wohlschlegel JA; Beck JR
    bioRxiv; 2023 Jul; ():. PubMed ID: 37503245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man.
    Li T; Yowell CA; Beyer BB; Hung SH; Westling J; Lam MT; Dunn BM; Dame JB
    Mol Biochem Parasitol; 2004 May; 135(1):101-9. PubMed ID: 15287591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting Plasmodium Plasmepsin V: Hitting Two Birds with One Stone.
    Brancucci NMB; Heussler VT; Grüring C
    Trends Parasitol; 2020 Feb; 36(2):85-87. PubMed ID: 31883707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Purification and characterization of a hemoglobin degrading aspartic protease from the malarial parasite Plasmodium vivax.
    Sharma A; Eapen A; Subbarao SK
    J Biochem; 2005 Jul; 138(1):71-8. PubMed ID: 16046450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding the structural basis of substrate recognition by Plasmodium falciparum plasmepsin V to aid in the design of potent inhibitors.
    Bedi RK; Patel C; Mishra V; Xiao H; Yada RY; Bhaumik P
    Sci Rep; 2016 Aug; 6():31420. PubMed ID: 27531685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
    Cunico W; Gomes CR; Facchinetti V; Moreth M; Penido C; Henriques MG; Varotti FP; Krettli LG; Krettli AU; da Silva FS; Caffarena ER; de Magalhães CS
    Eur J Med Chem; 2009 Sep; 44(9):3816-20. PubMed ID: 19403210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.
    Andrews KT; Fairlie DP; Madala PK; Ray J; Wyatt DM; Hilton PM; Melville LA; Beattie L; Gardiner DL; Reid RC; Stoermer MJ; Skinner-Adams T; Berry C; McCarthy JS
    Antimicrob Agents Chemother; 2006 Feb; 50(2):639-48. PubMed ID: 16436721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.